– USA, CA – TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics, a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, announced the appointment of Dr. Praveen Tipirneni (MD) to its Board as a non-executive director.
About Dr. Praveen Tipirneni
Dr. Praveen Tipirneni most recently served as President and CEO of Morphic Therapeutics Inc. from its founding until the acquisition by Eli Lilly for $3.2 billion.
Before founding Morphic, Dr. Praveen Tipirneni served as SVP of Corporate Development and Global Strategy at Cubist Pharmaceuticals from 2006 until the company’s acquisition by Merck in 2015 for approximately $9 billion. He also served as a 1st Lieutenant in the U.S. Army.
Dr. Praveen Tipirneni received a BS degree from Massachusetts Institute of Technology in Mechanical Engineering and an MD from McGill University. After completing his post-graduate residency in Internal Medicine at the University of Illinois, Chicago, he received his MBA in Healthcare Finance from the University of Pennsylvania’s Wharton School of Business.
About TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BBOT completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.
For more information: https://bridgebiooncology.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.